0001104659-23-008584.txt : 20230131 0001104659-23-008584.hdr.sgml : 20230131 20230131160430 ACCESSION NUMBER: 0001104659-23-008584 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230127 FILED AS OF DATE: 20230131 DATE AS OF CHANGE: 20230131 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ford David A CENTRAL INDEX KEY: 0001705295 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35668 FILM NUMBER: 23572543 MAIL ADDRESS: STREET 1: 7 OAKRIDGE ROAD CITY: ANNANDALE STATE: NJ ZIP: 08801 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INTERCEPT PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001270073 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 223868459 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 305 MADISON AVENUE CITY: MORRISTOWN STATE: NJ ZIP: 07960 BUSINESS PHONE: 646-747-1000 MAIL ADDRESS: STREET 1: 305 MADISON AVENUE CITY: MORRISTOWN STATE: NJ ZIP: 07960 FORMER COMPANY: FORMER CONFORMED NAME: INTERCEPT PHARMACEUTICALS INC DATE OF NAME CHANGE: 20031113 4 1 tm234878-3_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2023-01-27 0 0001270073 INTERCEPT PHARMACEUTICALS, INC. ICPT 0001705295 Ford David A C/O INTERCEPT PHARMACEUTICALS, INC. 305 MADISON AVENUE MORRISTOWN NJ 07960 0 1 0 0 Chief Human Resources Officer Common Stock 2023-01-27 4 A 0 9800 0 A 36438 D Option to Purchase Common Stock 18.40 2023-01-27 4 A 0 16000 0 A 2033-01-27 Common Stock 16000 16000 D Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2023. The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2023. /s/ Rocco Venezia, as attorney-in-fact 2023-01-31